Asset profile
Fulzerasib
Small molecule
Evidence outlook · no controlled comparison
NCT05756153 · Advance Non-small Cell Lung Cancer
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT05756153: The study was open-label, non-randomized, and had no comparator arm, with 47 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Interim analysis (ASCO 2024 late-breaking presentation, data cutoff before primary completion); single-arm response rate with no formal statistical threshold.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 9 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fulzerasib: this drug | Phase 3 | Small molecule | KRAS G12C | ||
| Sotorasib | Approved | Small molecule | KRAS G12C | ||
| Calderasib | Phase 3 | Small molecule | KRAS G12C | ||
| Divarasib | Phase 3 | Small molecule | KRAS G12C | ||
| Glecirasib | Phase 3 | Small molecule | KRAS G12C | ||
| JMKX001899 | Phase 3 | Small molecule | KRAS G12C | ||
| Elironrasib | Phase 1/2 | Small molecule | KRAS G12C | ||
| FMC-376 | Phase 1/2 | Small molecule | KRAS G12C | ||
| BBO-8520 | Phase 1 | Small molecule | KRAS G12C | ||
| HBI-2438 | Phase 1 | Small molecule | KRAS G12C | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (4)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (2)
May 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.